Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

  • STATUS
    Recruiting
  • End date
    Dec 31, 2022
  • participants needed
    38
  • sponsor
    Gachon University Gil Medical Center
Updated on 11 February 2021

Summary

A Phase 2 trial of avelumab plus gemcitabine in advanced leiomyosarcoma as a second line treatment

Details
Condition Leiomyosarcoma Metastatic
Treatment Avelumab and Gemcitabine
Clinical Study IdentifierNCT03536780
SponsorGachon University Gil Medical Center
Last Modified on11 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Unresectable, advanced or metastatic histologically confirmed leiomyosarcoma
Progression during or after first-line doxorubicin-based chemotherapy (relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy containing doxorubicin-based regimen could be considered as first-line therapy.)
ECOG PS 0-2
At least one measurable lesion according to RECIST v1.1
Adequate organ function
Life expectancy >= 3 months
Negative serum or urine pregnancy test at screening for women of childbearing potential

Exclusion Criteria

Prior treatment history of anti-PD-1/PD-L1 or anti-CTLA4 treatment
Receipt of 2 or more prior systemic treatments for advanced leiomyosarcoma
Active or untreated brain metastases or spinal cord compression
Prior treatment with gemcitabine
History of major surgery within 4 weeks prior to enrollment
Chemotherapy or radiotherapy within 3 weeks prior to the study drug commencement
Previous malignant disease other than leiomyosarcoma within the last 5 years with the exception of basal or squamous cell carcinoma of skin or carcinoma in situ (bladder, cervical, colorectal, breast)
Pregnant or lactating women
HIV, HBV, or HCV infection
Severe hypersensitivity or anaphylaxis to monoclonal antibody, or uncontrolled bronchial asthma
Current use of immunosuppressive agent (exclusion : less than prednisone 10 mg/day or equivalent)
Active autoimmune disease
Clinically significant cardiovascular disease
Clinically significant interstitial pneumonitis or pulmonary fibrosis
Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note